Inhibikase Therapeutics (IKT) AI Stock Analysis

• Market Cap: $206.15M
• Dividend Yield: N/A
• Average Volume (3M): 132.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.67
• Revenue Growth: -100.00%
• EPS Growth: 79.01%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 121,267,044
• 10 Day Avg. Volume: 124,469
• 30 Day Avg. Volume: 132,718
• PEG Ratio: 0.12
• Price to Book (P/B): 2.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.77
• Enterprise Value/Market Cap: 0.43
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.31K
• Enterprise Value/Ebitda: -1.73
• 1Y Price Target: $6.25
• Price Target Upside: 267.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $1.50 ▼(-11.76% Downside)

The score is held back primarily by the absence of revenue, recurring losses, and ongoing cash burn, despite a low-debt balance sheet. Technical indicators show strong upward momentum, and recent financing plus Phase 3 plans improve operational runway and catalyst potential, but dilution and loss-driven valuation constraints keep the overall score moderate.

Positive Factors

Low leverage / strong balance sheet

Minimal debt and a conservatively financed balance sheet reduce leverage-driven insolvency risk for a clinical-stage biotech. Low financial risk preserves strategic optionality to fund trials or partner programs and supports longer-term R&D execution without interest burdens.

Pipeline advancing to pivotal Phase 3

Progressing IKT-001 into a global pivotal Phase 3 is a structural de-risking event for a development-stage firm. A successful pivotal program can materially change the company's commercial prospects, enable partnering/licensing, and convert long-term R&D investment into potential revenue streams.

Demonstrated access to capital

Maintaining an active ATM program and executing underwritten financings shows durable access to public capital markets and institutional syndicates. That funding flexibility supports multi-stage clinical programs and reduces immediate liquidity stress versus sole reliance on one-time financings.

Negative Factors

No product revenue / persistent losses

As a development-stage company with zero recent revenue, Inhibikase remains structurally loss-making. Large and recurring net losses mean the firm must fund operations externally until commercialization, extending dependency on financing and increasing execution risk before sustainable revenues appear.

High operating cash burn

Sustained negative operating and free cash flow at scale requires repeated capital raises and shortens organic runway. Elevated cash burn pressures management to prioritize financing or partnerships, which can shift strategic choices and increase vulnerability if capital markets tighten.

Ongoing dilution risk from equity raises

Frequent and material equity offerings, including underwritten deals and an ATM, create structural dilution risk for shareholders. Regular issuance to fund trials can erode per-share economic value and complicate long-term investor returns unless offset by clear clinical or commercial milestones.

Inhibikase Therapeutics Business Overview & Revenue Model

Company Description

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

How the Company Makes Money

Inhibikase Therapeutics makes money through the development and commercialization of its pharmaceutical products. The company's revenue model is primarily based on advancing its drug candidates through clinical trials and achieving successful regulatory approvals. Key revenue streams include potential partnerships with larger pharmaceutical companies for the co-development or licensing of its therapies, as well as possible future revenues from product sales once the drugs reach the market. Additionally, the company may receive funding through research grants, collaborations, and milestone payments from strategic alliances, which help support its research and development efforts.

Inhibikase Therapeutics Financial Statement Overview

Summary

Inhibikase Therapeutics is facing significant financial challenges with diminishing total revenue, consistent net losses, and negative operating cash flow. The balance sheet is strong in terms of equity due to financing activities, but the company's reliance on external financing is concerning.

Income Statement

Inhibikase Therapeutics shows diminishing total revenue over the years, with a sharp drop to zero in the latest year. The company consistently reports negative net income, indicating ongoing losses. Margins such as EBIT and EBITDA are negative due to high expenses relative to the revenue. Revenue growth is negative when comparing to previous periods, highlighting challenges in revenue generation.

Balance Sheet

The company's balance sheet reflects a strong equity position relative to debt, as seen in the low debt-to-equity ratio. However, the high level of equity is primarily due to financing activities rather than retained earnings. The equity ratio is high, reflecting the company's reliance on equity financing. There is minimal debt, reducing leverage risks, but the persistent losses affect return on equity negatively.

Cash Flow

Operating cash flow remains negative, indicating the company is not generating positive cash from its core operations. While free cash flow is negative, indicating the company is spending more than it earns, there is considerable financing inflow, which supports liquidity. The ratios of cash flow to net income are unfavorable due to consistent net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	260.50K	123.44K	3.10M	698.47K
Gross Profit	-67.07K	-26.27K	-13.36M	116.72K	-8.26M	-195.33K
EBITDA	-50.95M	-27.49M	-19.91M	-18.05M	0.00	0.00
Net Income	-47.66M	-27.52M	-19.03M	-18.05M	-14.79M	-2.85M
Balance Sheet
Total Assets	79.59M	98.60M	14.51M	24.94M	42.47M	14.78M
Cash, Cash Equivalents and Short-Term Investments	77.32M	97.54M	13.25M	23.05M	40.75M	13.95M
Total Debt	0.00	110.52K	622.00K	351.29K	248.91K	319.00K
Total Liabilities	6.70M	3.73M	3.53M	3.90M	4.05M	5.00M
Stockholders Equity	72.90M	94.87M	10.98M	21.04M	38.42M	9.78M
Cash Flow
Free Cash Flow	-25.62M	-19.15M	-18.10M	-17.59M	-14.30M	-1.13M
Operating Cash Flow	-25.62M	-19.15M	-18.09M	-17.35M	-14.30M	-1.13M
Investing Cash Flow	-36.61M	-37.00M	11.66M	-16.01M	0.00	0.00
Financing Cash Flow	99.58M	103.48M	8.41M	-204.77K	41.09M	15.06M

Inhibikase Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IKT, the sentiment is Neutral. The current price of 1.7 is below the 20-day moving average (MA) of 1.79, above the 50-day MA of 1.64, and below the 200-day MA of 1.76, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 47.85 is Neutral, neither overbought nor oversold. The STOCH value of 12.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IKT.

Inhibikase Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IKT	54 Neutral	$206.15M	-2.98	-131.71%	―	-100.00%	79.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPRO	50 Neutral	$141.41M	-3.16	-95.29%	―	-67.38%	-1076.54%
SRZN	50 Neutral	$171.43M	-0.92	―	―	-63.96%	-28.50%
ANIX	49 Neutral	$110.48M	-9.83	-62.16%	―	―	11.78%
TCRX	49 Neutral	$68.10M	-1.07	-76.44%	―	-10.03%	11.06%
ATOS	45 Neutral	$77.76M	-2.57	-48.89%	―	―	-9.42%

Inhibikase Therapeutics Corporate Events

Inhibikase Updates ATM Equity Program to Raise Capital

On December 19, 2025, Inhibikase Therapeutics, Inc. filed a prospectus supplement with the U.S. Securities and Exchange Commission to update its existing at-the-market equity offering program, enabling the company to sell up to $185 million of its common stock from time to time through Jefferies LLC as sales agent under a previously executed open market sale agreement. The filing, made under an already effective shelf registration statement, reinforces the company’s ability to raise additional capital as needed, which may support ongoing operations and development programs while potentially diluting existing shareholders depending on the scale and timing of future share issuances.

The most recent analyst rating on (IKT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Inhibikase Therapeutics stock, see the IKT Stock Forecast page.

Inhibikase Therapeutics Announces $93.6 Million Stock Offering

On November 20, 2025, Inhibikase Therapeutics, Inc. announced an underwriting agreement for a public offering of common stock and pre-funded warrants, expected to raise approximately $93.6 million, with potential to increase to $107.7 million if the underwriters exercise their option in full. This financial move is part of the company’s strategy to support its clinical trial advancements, including the progression of IKT-001 to a global pivotal Phase 3 clinical trial in PAH, reflecting its commitment to expanding its therapeutic offerings in the biotechnology sector.

The most recent analyst rating on (IKT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inhibikase Therapeutics stock, see the IKT Stock Forecast page.

Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study

On November 20, 2025, Inhibikase Therapeutics announced plans to advance IKT-001 to a global pivotal Phase 3 clinical study for Pulmonary Arterial Hypertension, expected to begin in the first quarter of 2026. The study, named IMPROVE-PAH, will be conducted in two parts, with Part A focusing on pulmonary vascular resistance and Part B on the 6-minute walk distance. The company believes this adaptive study design offers significant advantages, such as a dose-titration phase and uninterrupted enrollment. Additionally, Inhibikase terminated its ATM Prospectus but maintained the Sales Agreement with Jefferies LLC, indicating a strategic shift in its financial operations.

The most recent analyst rating on (IKT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inhibikase Therapeutics stock, see the IKT Stock Forecast page.